Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis Report 2025

Alpha-1 antitrypsin deficiency (A1ATD) is a genetic disorder caused by mutations in the SERPINA1 gene, leading to the accumulation of abnormal alpha-1 antitrypsin protein in the liver. This accumulation can result in fibrosis, cirrhosis, and liver failure. According to Nikhil Khandelwal et al., 2025, approximately 1 in 4,500 to 1 in 2,750 individuals worldwide are affected by these mutations. Current therapies focus on symptom management, while emerging approaches target the underlying genetic defect. According to the alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline analysis by Expert Market Research, growing focus on gene therapy and RNA-based treatments is expected to witness significant growth in the coming years.

Report Coverage

The Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into alpha-1 antitrypsin deficiency (A1ATD) liver disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for alpha-1 antitrypsin deficiency (A1ATD) liver disease. The alpha-1 antitrypsin deficiency (A1ATD) liver disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with alpha-1 antitrypsin deficiency (A1ATD) liver disease treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to alpha-1 antitrypsin deficiency (A1ATD) liver disease.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Outlook

Alpha-1 antitrypsin deficiency (A1ATD) liver disease is a genetic disorder caused by mutations in the SERPINA1 gene, resulting in reduced circulating alpha-1 antitrypsin (AAT) protein and toxic accumulation of abnormal AAT in the liver. This buildup can lead to jaundice, cirrhosis, and progressive liver failure.

Treatments for alpha-1 antitrypsin deficiency (A1ATD) liver disease aim to manage liver damage and restore normal AAT levels. Current strategies include gene editing, liver-targeted therapies, and supportive care to slow disease progression and prevent complications. In March 2025, Prime Medicine unveiled a preclinical program leveraging liver-targeted Prime Editing to correct the Pi*Z mutation in the SERPINA1 gene, restoring wild-type AAT protein. This approach shows potential as a one-time curative therapy, with IND/CTA filing anticipated by mid-2026.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Epidemiology

According to Nikhil Khandelwal et al., 2025, alpha-1 antitrypsin deficiency (A1ATD) affects approximately 1 in 4,500 to 1 in 2,750 individuals globally. In the United States, 2% to 3% of patients with chronic obstructive pulmonary disease (COPD) have A1ATD. COPD impacted over 290 million people worldwide in 2019, ranking as the third leading cause of death. Older individuals with COPD are often diagnosed with A1ATD at advanced stages, resulting in more severe disease progression. This underscores the urgent need for targeted therapies in the A1ATD liver disease drug pipeline.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Pipeline Therapeutic Assessment

This section of the report covers the analysis of alpha-1 antitrypsin deficiency (A1ATD) liver disease drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

The alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral
• Parenteral
• Others

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total of alpha-1 antitrypsin deficiency (A1ATD) liver disease clinical trials, accounting for 35% of ongoing clinical development. Phase II follows closely at 25%, while phase III leads with 30%, reflecting a strong push toward late-stage clinical trials. This distribution underscores a robust progression from early discovery to advanced clinical testing, enhancing the potential for novel treatments to reach the market.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline analysis include small molecules, monoclonal antibodies and peptides. The alpha-1 antitrypsin deficiency (A1ATD) liver disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for alpha-1 antitrypsin deficiency (A1ATD) liver disease. Gene-editing therapies are emerging as a promising approach in the alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline. For example, BEAM-302, a liver-targeting lipid-nanoparticle formulation, is under investigation to correct the PiZ mutation in the SERPINA1 gene. By converting the mutant protein to its functional form, it aims to restore normal alpha-1 antitrypsin levels, reduce liver toxicity, and address both liver and lung complications.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Clinical Trials - Key Players

The report for the alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed alpha-1 antitrypsin deficiency (A1ATD) liver disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in alpha-1 antitrypsin deficiency (A1ATD) liver disease clinical trials:

• Takeda
• Wave Life Sciences Ltd.
• Krystal Biotech, Inc.
• Grifols Therapeutics LLC
• Sanofi
• BioMarin Pharmaceutical
• Kamada, Ltd.
• Beacon Therapeutics
• Inhibrx Biosciences, Inc.
• Vertex Pharmaceuticals Incorporated
• Beam Therapeutics Inc.

Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for alpha-1 antitrypsin deficiency (A1ATD) liver disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of alpha-1 antitrypsin deficiency (A1ATD) liver disease drug candidates.

Drug: Fazirsiran

Fazirsiran, sponsored by Takeda, is an investigational RNA interference (RNAi) therapy targeting the reduction of mutant alpha-1 antitrypsin protein (Z-AAT) in patients with alpha-1 antitrypsin deficiency liver disease (A1ATD-LD). This Phase 3 study is evaluating the long-term safety, tolerability, and potential effects on mild liver scarring (fibrosis) over a two-year period. Participants are receiving either fazirsiran or placebo, with liver biopsies conducted to monitor protein accumulation and disease progression.

Drug: WVE-006

WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide (AIMer) developed by Wave Life Sciences Ltd., targeting the Z mutation in SERPINA1 mRNA to convert Z-AAT into functional wild-type M-AAT. This Phase 1b/2a open-label study is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses in participants with Pi*ZZ AATD. WVE-006 is designed to reduce liver protein aggregation while increasing circulating AAT, addressing both lung and liver disease manifestations.

Key Questions Answered in the Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Insight Report

• Which companies/institutions are leading the of alpha-1 antitrypsin deficiency (A1ATD) liver disease drug development?
• Which company is leading the of alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline development activities?
• What is the current of alpha-1 antitrypsin deficiency (A1ATD) liver disease commercial assessment?
• What are the opportunities and challenges present in the alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline landscape?
• What is the efficacy and safety profile of alpha-1 antitrypsin deficiency (A1ATD) liver disease pipeline drugs?
• Which company is conducting major trials for of alpha-1 antitrypsin deficiency (A1ATD) liver disease drugs?
• Which companies/institutions are involved in alpha-1 antitrypsin deficiency (A1ATD) liver disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in alpha-1 antitrypsin deficiency (A1ATD) liver disease?

Reasons To Buy This Report

The Alpha-1 Antitrypsin Deficiency (A1ATD) Liver Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for alpha-1 antitrypsin deficiency (A1ATD) liver disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into alpha-1 antitrypsin deficiency (A1ATD) liver disease collaborations, regulatory environments, and potential growth opportunities.

This product will be delivered within 3-5 business days.